On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

ET on May 2Cigna is doubling down on its efforts to manage the challenges associated with GLP-1s through the launch of two ...

The Cigna Group reported a strong start to the year, with first-quarter 2025 revenues rising 14% to $65.5 billion.

May 2, 2025Cigna Corporation beats earnings expectations. Reported EPS is $6.74, expectations were $6.35. Operator: Ladies and gentlemen, thank you for standing by for The Sector Group's First Quarter ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Q1 2025 Earnings Conference Call May 2, 2025 8:30 AM ETCompany ParticipantsRalph Giacobbe - Senior Vice President, ...

Cigna and Singleton Associates ... “Bringing high-quality radiology care in network doesn’t just improve patient access—it lowers healthcare costs and simplifies the system for everyone ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...